On February 16, 2021 Oasmia Pharmaceutical reported that it will publish its Year-end report for the shortened financial year May 1, 2020 – December 31, 2020 on February 19, 2021, at 08.00 am CET (Press release, Oasmia, FEB 16, 2021, View Source [SID1234575111]). The company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by CEO Francois Martelet, CEO and Acting CFO Robert Maiorana. The presentation will be in English.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 16, 2021 AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 6,250,000 shares of common stock of the Company at a price to the public of $1.60 per share, less underwriting discounts and commissions (Press release, AIkido Pharma, FEB 16, 2021, View Source [SID1234575147]). The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

The Company also has granted to the underwriter a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price, less underwriting discounts and commission.

The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The offering is being conducted pursuant to the registration statement on Form S-3 (File No. 333-238172), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC") on June 18, 2020. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at View Source Electronic copies of the final prospectus relating to this offering, when available, may be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at [email protected] or by telephone at 646-975-6996. Before investing in this offering, interested parties should read in their entirety the registration statement that the Company has filed with the SEC, which provides additional information about the Company and this offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On February 16, 2021 Nanocan Therapeutics Corporation, an early-stage biotechnology company, reported an exclusive global licensing agreement with Brigham and Women’s Hospital (Boston, MA), a teaching hospital of Harvard University’s Medical School, to develop and commercialize Immunogenic Smart Radiotherapy Biomaterials (iSRBs) for the treatment of pancreatic, lung, and cervical cancer (Press release, Nanocan Therapeutics, FEB 16, 2021, View Source [SID1234625677]). This technology has the potential to enhance radiotherapy mechanisms via delivery of immunoadjuvants that improve both local and metastatic tumor kill. iSRBs could also potentially reduce treatment time and cost for cancer patients, improve convenience, and significantly improve global patient access to cancer treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

iSRBs can provide both CT and MRI imaging contrast crucial for image-guided radiotherapy and can also provide sustained delivery of immunoadjuvant payloads. In conjunction with an immunoadjuvant, a boost in abscopal effect causing regression in both treated and untreated tumors has been observed in animal models, with minimal normal tissue toxicity.

"Pancreatic cancer, our lead indication, remains a challenging diagnosis with high mortality," said Eric Broyles, Founder and CEO of Nanocan Therapeutic Corporation. "With our expertise in nanotechnology delivery, and grant investments from the NIH, NCI, and DoD, Nanocan is well positioned to further develop iSRBs in pursuit of providing a new standard of care for pancreatic, lung, and cervical cancers. We also see potential application in breast, liver, and prostate cancers, as well as glioblastoma."

We’re encouraged by the research undertaken by scientists at Brigham and Women’s Hospital and excited about this global licensing agreement," said Jack Markell, two-term Governor of Delaware and Nanocan Advisory Board member. "We are deeply committed to improving the lives of cancer patients around the world and will place a special emphasis on bringing these life-saving technologies to underserved and developing countries."

On February 16, 2021 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, reported that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 10th Annual Global Healthcare Conference taking place February 24 – 26, 2021 (Press release, Selecta Biosciences, FEB 16, 2021, View Source [SID1234575090]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation on Friday, February 26 at 10 a.m. ET will be available through the SVB Leerink Conference portal and an archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

On February 16, 2021 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported that it is scheduled to speak at Citi’s 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference (Press release, Quest Diagnostics, FEB 16, 2021, View Source [SID1234575112]). Mark Guinan, Executive Vice President & CFO will discuss the company’s vision, goals, and capital deployment strategies. The presentation is scheduled for Wednesday, February 24, 2021 at 1:30 p.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live during the conference and will be available on the company’s investor relations page which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 48 hours after the conclusion of the live event and will remain available until March 26, 2021.